Kohorn Ernest I
Department of Gynecology and Obstetrics, Yale University School of Medicine, New Haven, Connecticut, USA.
J Reprod Med. 2002 Jun;47(6):445-50.
To discuss the current problems in establishing a unified staging and risk factor scoring system for trophoblastic disease under the auspices of the International Federation of Gynecology and Obstetrics (FIGO).
To present a history of the classifications of trophoblastic disease and compare these with the proposals presented to FIGO by the International Society for the Study of Trophoblastic Disease, the International Gynecologic Cancer Society and the Society of Gynecologic Oncologists.
The situation concerning the proposed 2000 FIGO trophoblast classification was resolved by FIGO's acceptance of the recommendations outlined in this paper.
There is a scientific and clinical need for FIGO to adopt the recommendations of the majority of physicians with expertise in treating trophoblastic disease for a rational classification of trophoblastic disease. It is gratifying that FIGO has done so.
探讨在国际妇产科联盟(FIGO)主持下建立统一的滋养细胞疾病分期及危险因素评分系统过程中目前存在的问题。
介绍滋养细胞疾病分类的历史,并将其与国际滋养细胞疾病研究学会、国际妇科癌症学会和妇科肿瘤学家学会提交给FIGO的提议进行比较。
FIGO接受了本文概述的建议,从而解决了关于2000年FIGO滋养细胞分类提议的相关情况。
FIGO有科学和临床需求采用大多数治疗滋养细胞疾病的专家的建议,以便对滋养细胞疾病进行合理分类。令人欣慰的是,FIGO已经这样做了。